Key result
High soluble ST2 levels (≥35 ng/mL) were associated with a significantly higher rate of postoperative adverse events compared to low levels (100% vs 26%; OR 1.117, 95% CI 1.016–1.228).
Why the study?
The study was conducted to investigate the prognostic value of soluble ST2 in predicting postoperative adverse events in patients with impaired left ventricular function undergoing CABG surgery.
Does high soluble ST2 predict postoperative adverse events in patients with stable CAD and impaired LV function undergoing CABG?
Cohort (n=80)
Does high soluble ST2 predict postoperative adverse events in patients with stable CAD and impaired LV function undergoing CABG?
Odds Ratio: 1.117 (95% CI 1.016–1.228)
Absolute Event Rate: 100% vs 26%
p-value: p=0.022
Preoperative soluble ST2 levels can independently predict adverse postoperative outcomes in patients with stable CAD and reduced LVEF undergoing CABG.
High soluble ST2 may flag higher postoperative risk in CABG; hypothesis-generating and requires prospective validation before clinical use.
Background and Objectives: The aim of this study was to investigate the prognostic value of soluble ST2 (sST2) in predicting postoperative adverse events in patients with impaired left ventricular (LV) function undergoing coronary artery bypass graft (CABG) surgery. Materials and Methods: This study included 80 consecutive patients with stable coronary artery disease (CAD) and impaired LV function (ejection fraction ≤ 45%) undergoing on-pump coronary artery bypass graft surgery. The patients were divided into the “high” or “low” group according to their ST2 levels (≥35 or <35 ng/mL). Results: Postoperative adverse events were more common in patients with high sST2 levels than in patients with low sST2 levels (100% vs 26%, p < 0.0001). Multivariate analysis showed that sST2 level was an independent predictor of the presence of postoperative adverse events (OR: 1.117 (95% CI: 1.016–1.228), p = 0.022). The receiver operating characteristic curve (ROC) analysis of sST2 revealed an area under the curve (AUC) of 0.812 (95% CI: 0.710–0.913, p < 0.001) in predicting postoperative adverse events. An sST2 level of 26.50 ng/ml was identified as the optimal cut-off value, with a sensitivity and specificity of 74.1% and 75.3%, respectively. Conclusion: Higher sST2 levels were associated with adverse outcomes after CABG in patients with impaired LV and stable CAD.
No takes yet. Share an insight, caveat, or question.
Dolapoğlu et al. (2019) conducted a cohort in Stable coronary artery disease with impaired left ventricular function undergoing CABG (n=80). High soluble ST2 (sST2) levels (≥35 ng/mL) vs. Low sST2 levels (<35 ng/mL) was evaluated on Postoperative adverse events (OR 1.117, 95% CI 1.016–1.228, p=0.022). High soluble ST2 levels (≥35 ng/mL) were associated with a significantly higher rate of postoperative adverse events compared to low levels (100% vs 26%; OR 1.117, 95% CI 1.016–1.228).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: